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I. INTRODUCTION
Treatment-resistant depression (TRD) is a significant clinical problem with approximately two-thirds of patients with major depressive disorder (MDD) not achieving remission after the first trial of antidepressant medications and one-third of patients remaining symptomatic following multiple sequential trials of antidepressant medication [1] . Other patients are unable to tolerate antidepressant medications [2, 3] . Although treatments such as electroconvulsive therapy (ECT) are highly efficacious [4] [5] [6] , tolerability of ECT can be low due to potential cognitive side effects [7] . Newer magnetic stimulation treatments such as repetitive transcranial magnetic stimulation (rTMS) have shown clinical efficacy, reproduced in meta-analyses [8] [9] [10] , and have a better side effect profile than ECT and many medications. However, the standard rTMS treatment protocol requires daily 40-minute sessions, continuously for 4-6 weeks, and therefore is inconvenient and costly for patients.
Low field magnetic stimulation may offer an alternative to patients who do not remit with traditional pharmacologic approaches. LFMS employs the unique magnetic field waveform used in echo-planar magnetic resonance spectroscopic imaging to deliver a low intensity, time-varying electric field in the brain (E ≤ 1 V/m, 1 kHz). Unlike TMS, LFMS does not evoke neuronal action potentials, but has been shown to modulate metabolism in broad regions of human cerebral cortex [11] , and to modulate spontaneous neuronal oscillations in rodent slice preparations [12, 13] . LFMS also had significant antidepressant-like behavioral effects in a rodent model, reducing immobility in a forced swim test protocol [14] . However, mood enhancement has been equivocal in humans with MDD, with recent single and multi-site randomized controlled trials missing targets on their primary outcome variables, while showing some positive results on select secondary outcomes [15, 16] . This is in contrast to somewhat more consistent positive mood-enhancing results for bipolar depression [16, 17] . LFMS may have safety advantages over TMS that could broaden its clinical applicability. Because it is subthreshold, it does not require periodic monitoring of motor threshold. Therefore, it is likely to be better tolerated than TMS, carry a lower seizure risk, and thus could potentially be administered in an unsupervised setting.
The main objectives of this study were to examine the mood effects of LFMS on patients with TRD and to explore dosing in terms of number of treatment sessions. To this end, we undertook a double-blind randomized controlled trial of 3 sessions of LFMS for TRD. We hypothesized that relative to participants randomized to the sham condition, measures of mood would be greater in the active LFMS group immediately after session 3. In an exploratory analysis, we investigated whether a difference in measures of mood emerged earlier, after the first or second treatment session.
II. METHODS
This was a single-site, double-blind, randomized, sham-controlled phase II study of the efficacy of LFMS on mood symptoms in TRD. Eligible participants were randomly assigned to double-blind treatment with three 20-minute sessions of either active or sham LFMS. This trial was conducted according to the U.S. Food and Drug Administration guidelines (https: //clinicaltrials.gov/ct2/show/NCT01944644) and the Declaration of Helsinki. Written informed consent was obtained from all participants before protocol-specified procedures were carried out. The participants were drawn from an outpatient sample of patients with current MDD. All aspects of our experimental protocol were approved by the Institutional Review Board of Weill Cornell Medical College and conducted in accordance with institutional guidelines.
A. Participants
The Principal Investigator (MJD) screened participants for eligibility criteria (below) as outlined in the Study Flowchart ( Figure 1 ). In cases in which the participant was unable to answer all relevant questions regarding their psychiatric history, additional history was obtained from current and past psychiatric treaters. A HIPAA release was obtained from the participant when this additional history was required. Treatment-resistance was defined as the failure to respond to one or more trials of an adequate dose of an antidepressant for at least 8 weeks and was documented using the MGH Antidepressant Treatment Response Questionnaire (MGH ATRQ) [18] [19] [20] . In addition, if currently on psychotropic medication, participants must have been taking the current doses of all medications in their current regimen for the past four weeks [21, 22] . Thirty participants were recruited who met the following inclusion and exclusion criteria. f) Women of childbearing potential (WOCBP) were required to be using an adequate method of contraception to avoid pregnancy throughout the study and must have had a negative urine pregnancy test within 72 hours prior to the start of LFMS.
2) Exclusion Criteria: A participant was ineligible for participation in the study if any of the following criteria were met: a) WOCBP who were unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period. 
B. Study Design
All participants in the intent-to-treat group were randomized with a 1 : 1 ratio to LFMS or sham. All LFMS sessions were 20 min in duration. Mood-enhancing response was evaluated by assessing changes in three primary outcome measures immediately prior to and immediately after each LFMS or sham session. The three measures were: the observer-rated 6-item Hamilton Depression Rating Scale (HAMD-6) [23, 24] , the participant-rated Positive and Negative Affect Scale (PANAS) [25] , and the participantrated Visual-Analog Mood Scale (VAS), assessing sad-happy, withdrawn-social, tense-relaxed, slow-quick, and hostile-friendly. The VAS score was defined as the average of these five components [26] [27] [28] . The HAMD-6 ratings were conducted by two research assistants trained by certified HAMD raters (MJD and JK).
If the HAMD-6 declined by 25% or greater, either between successive treatments or from before to after a given treatment, the participant was terminated from the study. The Principal Investigator evaluated the participant for acute risk of suicide. If the participant was determined to be at acute risk for suicide, the participant was brought to the psychiatric emergency room at Weill Cornell for further evaluation. Follow-up care with the participant's outside psychiatrist was arranged by the Principal Investigator.
C. LFMS Protocol
LFMS followed a previously published protocol for the treatment of a Major Depressive Episode [17] . LFMS treatments were delivered with a prototype LFMS device manufactured by or sham treatment so that the participant, operator, and all investigators were blinded to active treatment vs. sham. Immediately before and after each treatment session, the HAMD-6, PANAS, and VAS were administered and the participant was monitored for any adverse events.
D. Adverse Events
Observed and spontaneously-reported adverse events were recorded at each visit. Spontaneouslyreported adverse events were classified as mild, moderate or severe. Participants were allowed to contact the principal investigator or a member of the study team at any time between visits concerning adverse events or worsening of symptoms.
E. Statistical Analysis Plan
Descriptive statistics (including mean, standard deviation, frequency, and percent) for demographic and baseline clinical severity factors were calculated to characterize the active LFMS and sham groups (both for per-protocol and intent-to-treat). The two-sample t-test or χ 2 -test were used, as appropriate, to compare demographic and baseline clinical severity factors between the active LFMS and sham groups. Analysis of covariance (ANCOVA) was used to compare mood ratings (i.e., HAMD-6, PANAS-Positive, PANAS-Negative, and VAS; 4 separate AN-COVA models) at the final session between the active and sham groups, controlling for age, gender, and baseline mood score. In cases of missing data, the last-observation-carried-forward Table 1 shows the demographic characteristics and baseline clinical severity of the sample.
III. RESULTS

A. Demographics and Sample Characteristics
Active LFMS and sham groups did not differ significantly in age, gender, race or baseline clinical severity measured by any of the 3 primary outcome variables. Table 2 shows the means and standard deviations of mood ratings (HAMD-6, PANAS-Positive, PANAS-Negative, and VAS) in the active-LFMS and sham groups at baseline and upon completion of the third and final treatment session. To examine whether mood ratings differed between active and sham LFMS at the conclusion of treatment, we conducted three ANCOVAs (analyses of covariance), with intervention (active, sham) as a between-participants factor and age, sex and baseline mood rating as covariates. The three dependent variables were scores for the primary outcome variables (HAMD-6, PANAS-Negative, and VAS) post-intervention. The effect of active LFMS on VAS and HAMD-6 emerged superior to sham (F (1, 24) = 7.45, p = 0.03, Holm- 
B. LFMS Effects on Mood
P-values are for Student's t-tests
Active and sham groups did not differ on any demographic variables. Additionally, baseline clinical severity did not differ significantly between active and sham groups with the exception of the sham group having higher baseline PANAS-Negative scores † Significant difference between LFMS and sham (uncorrected) Bonferroni corrected; F (1, 22) = 6.92, p = 0.03, Holm-Bonferroni corrected, respectively).
Additionally, to address dosing, we asked how early in the course of treatment significant differences emerge between the mood effects of active LFMS and sham. We conducted ANCOVAs with intervention (active, sham) as a between-participants factor and age, sex and baseline mood rating as covariates. The dependent variables were mood scores (HAMD-6, PANAS-Negative, and VAS) during the two mid-intervention (following the second LFMS session) assessment points.
Among these tests, the mid-treatment differences between active LFMS and sham did not reach significance on HAMD-6, PANAS-Negative, or VAS after correcting for multiple comparisons.
C. Effectiveness of Sham
For the 24 participants who completed a questionnaire about whether they believed they were in the active LFMS or sham condition, participants were not more likely than chance to correctly identify the intervention condition they were blind to (χ 2 = 0.001, p = 0.97). 
D. Safety and Tolerability of LFMS
LFMS was tolerable. One participants dropped out after the first treatment because of serious clinical events, but these were deemed to be unrelated to the treatment itself. We observed no treatment-emergent suicidality. One subject who received sham was hospitalized 2 weeks after completion of the study for worsening depression and suicidal ideation.
IV. DISCUSSION
The principal finding of this study is that in a double-blinded sham-controlled study, 2 of 3 primary outcome variables of mood symptoms, namely the HAMD-6 and VAS, showed greater improvement after three treatments in the active LFMS group than in sham LFMS. This is the first study to demonstrate mood-enhancing effects of LFMS in treatment-resistant unipolar depression. The fact that 3 treatment sessions were required for a significant mood-enhancing effect to emerge between active and sham LFMS for TRD suggests that unipolar TRD may require more treatments than bipolar depression for a similar response. This is in keeping with bipolar depression responding faster than unipolar depression to ECT [29, 30] .
Mood enhancements were unlikely to be attributable to sham because of the high quality of the sham-participants from active and sham groups guessed that they received active treatment at chance. Additionally, the mood-enhancing effect of the sham waned with subsequent treatments, an effect observed in other double-blinded, sham-controlled trials of brain stimulation treatments, including TMS [31] .
The main limitation of our study is the lack of follow-up mood assessments and the short In addition to the limited mood assessment window, the use of the HAMD-6, although consistent with previous studies of LFMS, was a limitation of this study because of the time frame it refers to. Although we changed the time frame from 7 days to 48 hrs, the HAMD has still been validated only for the 7-day time period and this may have been a less appropriate assessment than the VAS or PANAS to capture transient effects on mood.
In summary, LFMS may be a promising, well-tolerated treatment for TRD with a potentially rapid onset of action. In addition to optimizing the dosing protocol and testing the durability of the mood improvments, we need to better characterize the subgroup of patients who respond to LFMS. Using functional neuroimaging to understand the circuit abnormalities that are predictive of treatment response has shown great promise for TMS [32] [33] [34] [35] [36] [37] [38] . Mapping these abnormalities in LFMS responders could eventually help match the treatment to depressed patients most likely to benefit and will guide advancements in LFMS coil design to optimize treatment [39, 40] . 
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